Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALXO NASDAQ:CAPR NASDAQ:ORIC NASDAQ:WVE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.03+0.5%$1.88$0.51▼$2.66$273.16M0.421.65 million shs1.01 million shsCAPRCapricor Therapeutics$19.70-0.7%$25.29$4.30▼$40.37$1.14B0.421.78 million shs2.46 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.25B1.021.57 million shs3.61 million shsWVEWAVE Life Sciences$5.81+0.5%$6.03$5.02▼$21.73$1.12B-1.292.57 million shs2.07 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology+0.50%-3.33%+13.41%+21.56%+301.03%CAPRCapricor Therapeutics-0.66%+1.34%-33.24%-44.15%+188.86%ORICOric Pharmaceuticals+11.11%+12.77%+28.31%+18.16%+2.54%WVEWAVE Life Sciences+0.52%-0.17%-2.35%-19.08%-32.13%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALXOALX Oncology$2.03+0.5%$1.88$0.51▼$2.66$273.16M0.421.65 million shs1.01 million shsCAPRCapricor Therapeutics$19.70-0.7%$25.29$4.30▼$40.37$1.14B0.421.78 million shs2.46 million shsORICOric Pharmaceuticals$12.10+11.1%$9.39$7.23▼$14.93$1.25B1.021.57 million shs3.61 million shsWVEWAVE Life Sciences$5.81+0.5%$6.03$5.02▼$21.73$1.12B-1.292.57 million shs2.07 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALXOALX Oncology+0.50%-3.33%+13.41%+21.56%+301.03%CAPRCapricor Therapeutics-0.66%+1.34%-33.24%-44.15%+188.86%ORICOric Pharmaceuticals+11.11%+12.77%+28.31%+18.16%+2.54%WVEWAVE Life Sciences+0.52%-0.17%-2.35%-19.08%-32.13%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALXOALX Oncology 2.67Moderate Buy$4.60126.60% UpsideCAPRCapricor Therapeutics 2.90Moderate Buy$53.67172.42% UpsideORICOric Pharmaceuticals 2.75Moderate Buy$19.2759.28% UpsideWVEWAVE Life Sciences 2.94Moderate Buy$26.41354.59% UpsideCurrent Analyst Ratings BreakdownLatest ALXO, CAPR, WVE, and ORIC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2026WVEWAVE Life Sciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/17/2026ORICOric Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026WVEWAVE Life Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/26/2026ALXOALX Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/25/2026CAPRCapricor Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/12/2026ORICOric Pharmaceuticals Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$14.006/11/2026WVEWAVE Life Sciences New Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$13.006/11/2026WVEWAVE Life Sciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026ORICOric Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALXOALX OncologyN/AN/AN/AN/A$0.48 per shareN/ACAPRCapricor Therapeutics$22.27M51.23N/AN/A$5.53 per share3.56ORICOric PharmaceuticalsN/AN/AN/AN/A$3.90 per shareN/AWVEWAVE Life Sciences$42.73M26.16N/AN/A$3.10 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALXOALX Oncology-$101.69M-$1.49N/AN/AN/AN/A-124.06%-85.57%8/11/2026 (Estimated)CAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)ORICOric Pharmaceuticals-$129.47M-$1.44N/AN/AN/AN/A-35.33%-33.31%8/11/2026 (Estimated)WVEWAVE Life Sciences-$204.38M-$1.06N/AN/AN/A-255.70%-56.76%-42.80%7/30/2026 (Estimated)Latest ALXO, CAPR, WVE, and ORIC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026ALXOALX Oncology-$0.15N/AN/AN/AN/AN/A8/11/2026Q2 2026CAPRCapricor Therapeutics-$0.58N/AN/AN/A$2.08 millionN/A8/11/2026Q2 2026ORICOric Pharmaceuticals-$0.36N/AN/AN/AN/AN/A7/30/2026Q2 2026WVEWAVE Life Sciences-$0.31N/AN/AN/A$7.45 millionN/A5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/8/2026Q1 2026ALXOALX Oncology-$0.15-$0.17-$0.02-$0.17N/AN/A5/4/2026Q1 2026ORICOric Pharmaceuticals-$0.31-$0.34-$0.03-$0.34N/AN/A4/29/2026Q1 2026WVEWAVE Life Sciences-$0.34-$0.13+$0.21-$0.13$8.45 million$38.25 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALXOALX OncologyN/AN/AN/AN/AN/ACAPRCapricor TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/AWVEWAVE Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALXOALX Oncology0.027.217.21CAPRCapricor TherapeuticsN/A8.428.42ORICOric PharmaceuticalsN/A16.3316.33WVEWAVE Life SciencesN/A11.2611.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALXOALX Oncology97.97%CAPRCapricor Therapeutics21.68%ORICOric Pharmaceuticals95.05%WVEWAVE Life Sciences89.73%Insider OwnershipCompanyInsider OwnershipALXOALX Oncology21.00%CAPRCapricor Therapeutics9.20%ORICOric Pharmaceuticals5.70%WVEWAVE Life Sciences24.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALXOALX Oncology40134.56 million106.31 millionOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableORICOric Pharmaceuticals80103.52 million97.62 millionOptionableWVEWAVE Life Sciences240192.40 million145.65 millionOptionableALXO, CAPR, WVE, and ORIC HeadlinesRecent News About These CompaniesAffinity Asset Advisors LLC Decreases Stake in WAVE Life Sciences Ltd. $WVEJuly 25 at 3:12 AM | marketbeat.comWave Life Sciences (WVE) Stock Looks Cheap On Price But Expensive On SalesJuly 24 at 1:07 AM | finance.yahoo.comWave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026July 23 at 9:00 AM | globenewswire.comZacks Research Upgrades WAVE Life Sciences (NASDAQ:WVE) to "Strong-Buy"July 23 at 6:41 AM | marketbeat.comWAVE Life Sciences (WVE) to Release Quarterly Earnings on ThursdayJuly 23 at 2:26 AM | americanbankingnews.comWAVE Life Sciences (WVE) to Post Earnings on ThursdayJuly 23 at 2:25 AM | marketbeat.comWave Life Sciences (WVE) Upgraded to Strong Buy: What Does It Mean for the Stock?July 22 at 1:02 PM | zacks.comNew Strong Buy Stocks for July 22ndJuly 22 at 8:17 AM | zacks.com3 Promising Genomics Stocks to Add to Your Portfolio in 2026July 20, 2026 | zacks.comWAVE Life Sciences Ltd. (NASDAQ:WVE) Given Average Rating of "Moderate Buy" by AnalystsJuly 16, 2026 | marketbeat.comWAVE Life Sciences Ltd. $WVE Position Reduced by Emerald Advisers LLCJuly 14, 2026 | marketbeat.comEmerald Mutual Fund Advisers Trust Sells 600,136 Shares of WAVE Life Sciences Ltd. $WVEJuly 14, 2026 | marketbeat.comWAVE Life Sciences (NASDAQ:WVE) Trading Down 8.3% - What's Next?July 10, 2026 | marketbeat.comWave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for RedomiciliationJuly 7, 2026 | globenewswire.comDoes Wave Life Sciences (WVE) Have the Potential to Rally 294.66% as Wall Street Analysts Expect?July 1, 2026 | zacks.comWave Life Sciences (WVE) Initiates Multidose Phase 2a for INLIGHTTM TrialJune 30, 2026 | insidermonkey.comWave Life Sciences Shareholders Approve Redomiciliation SchemeJune 26, 2026 | tipranks.comWave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic DiseasesJune 24, 2026 | globenewswire.comWave Life Sciences (WVE) Upgraded to Buy: Here's WhyJune 16, 2026 | zacks.comIs Wave Life Sciences Ltd. (WVE) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comMizuho Securities Remains a Buy on Wave Life Sciences (WVE)June 13, 2026 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026AirJoule Unveils Prime System, Clearing Path to CommercializationBy Thomas Hughes | July 1, 2026Capri's Turnaround Is Taking Shape, But Is the Stock a Buy Yet?By Jennifer Ryan Woods | June 28, 2026ALXO, CAPR, WVE, and ORIC Company DescriptionsALX Oncology NASDAQ:ALXO$2.03 +0.01 (+0.50%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.02 0.00 (-0.25%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.Capricor Therapeutics NASDAQ:CAPR$19.70 -0.13 (-0.66%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.80 +0.11 (+0.53%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Oric Pharmaceuticals NASDAQ:ORIC$12.10 +1.21 (+11.11%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$12.14 +0.04 (+0.29%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.WAVE Life Sciences NASDAQ:WVE$5.81 +0.03 (+0.52%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$5.78 -0.03 (-0.52%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
